TY - JOUR
T1 - Cell and molecular targeted therapies for diabetic retinopathy
AU - Reddy, Shivakumar K.
AU - Devi, Vasudha
AU - Seetharaman, Amritha T.M.
AU - Shailaja, S.
AU - Bhat, Kumar M.R.
AU - Gangaraju, Rajashekhar
AU - Upadhya, Dinesh
N1 - Publisher Copyright:
Copyright © 2024 Reddy, Devi, Seetharaman, Shailaja, Bhat, Gangaraju and Upadhya.
PY - 2024
Y1 - 2024
N2 - Diabetic retinopathy (DR) stands as a prevalent complication in the eye resulting from diabetes mellitus, predominantly associated with high blood sugar levels and hypertension as individuals age. DR is a severe microvascular complication of both type I and type II diabetes mellitus and the leading cause of vision impairment. The critical approach to combatting and halting the advancement of DR lies in effectively managing blood glucose and blood pressure levels in diabetic patients; however, this is seldom achieved. Both human and animal studies have revealed the intricate nature of this condition involving various cell types and molecules. Aside from photocoagulation, the sole therapy targeting VEGF molecules in the retina to prevent abnormal blood vessel growth is intravitreal anti-VEGF therapy. However, a substantial portion of cases, approximately 30-40%, do not respond to this treatment. This review explores distinctive pathophysiological phenomena of DR and identifiable cell types and molecules that could be targeted to mitigate the chronic changes occurring in the retina due to diabetes mellitus. Addressing the significant research gap in this domain is imperative to broaden the treatment options available for managing DR effectively.
AB - Diabetic retinopathy (DR) stands as a prevalent complication in the eye resulting from diabetes mellitus, predominantly associated with high blood sugar levels and hypertension as individuals age. DR is a severe microvascular complication of both type I and type II diabetes mellitus and the leading cause of vision impairment. The critical approach to combatting and halting the advancement of DR lies in effectively managing blood glucose and blood pressure levels in diabetic patients; however, this is seldom achieved. Both human and animal studies have revealed the intricate nature of this condition involving various cell types and molecules. Aside from photocoagulation, the sole therapy targeting VEGF molecules in the retina to prevent abnormal blood vessel growth is intravitreal anti-VEGF therapy. However, a substantial portion of cases, approximately 30-40%, do not respond to this treatment. This review explores distinctive pathophysiological phenomena of DR and identifiable cell types and molecules that could be targeted to mitigate the chronic changes occurring in the retina due to diabetes mellitus. Addressing the significant research gap in this domain is imperative to broaden the treatment options available for managing DR effectively.
UR - http://www.scopus.com/inward/record.url?scp=85197451311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85197451311&partnerID=8YFLogxK
U2 - 10.3389/fendo.2024.1416668
DO - 10.3389/fendo.2024.1416668
M3 - Review article
AN - SCOPUS:85197451311
SN - 1664-2392
VL - 15
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1416668
ER -